{'fraction_non_alphanumeric': 0.011945392491467578, 'fraction_numerical': 0.006825938566552901, 'mean_word_length': 6.072289156626506, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Is p53 Overexpression a Predictor of Worse Outcomes in Endometrioid Endometrial Carcinomas?

Endometrial cancer (EC) is the most common neoplasm of the female genital tract. Although immunohistochemical methods have been used for detecting several biomarkers for several cancer types, this method is still underutilized in EC. We conducted this review to identify the currently available published evidence to support the utilization of immunohistochemical for p53 protein overexpression as prognostic and predictive biomarkers of disease outcomes in endometrioid endometrial carcinoma.